Treprostinil (injection)

Revision as of 17:05, 20 August 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
Jump to navigation Jump to search
Treprostinil (injection)
Clinical data
Pregnancy
category
  • B
Routes of
administration
Subcutaneous or intravenous infusion
ATC code
Legal status
Legal status
  • ?
Pharmacokinetic data
Bioavailabilityapproximately 100%
MetabolismTreprostinil is substantially metabolized by the liver, but the involved enzymes are not currently known. Five metabolites (HU1 through HU5) have been identified thus far.
Elimination half-life4 hours
ExcretionUrine (4% as unchanged drug, 64% as metabolites); feces (13%)
Identifiers
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC23H33NaO5
Molar massrelative molecular weight is 412.49 g/mol.

WikiDoc Resources for Treprostinil (injection)

Articles

Most recent articles on Treprostinil (injection)

Most cited articles on Treprostinil (injection)

Review articles on Treprostinil (injection)

Articles on Treprostinil (injection) in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Treprostinil (injection)

Images of Treprostinil (injection)

Photos of Treprostinil (injection)

Podcasts & MP3s on Treprostinil (injection)

Videos on Treprostinil (injection)

Evidence Based Medicine

Cochrane Collaboration on Treprostinil (injection)

Bandolier on Treprostinil (injection)

TRIP on Treprostinil (injection)

Clinical Trials

Ongoing Trials on Treprostinil (injection) at Clinical Trials.gov

Trial results on Treprostinil (injection)

Clinical Trials on Treprostinil (injection) at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Treprostinil (injection)

NICE Guidance on Treprostinil (injection)

NHS PRODIGY Guidance

FDA on Treprostinil (injection)

CDC on Treprostinil (injection)

Books

Books on Treprostinil (injection)

News

Treprostinil (injection) in the news

Be alerted to news on Treprostinil (injection)

News trends on Treprostinil (injection)

Commentary

Blogs on Treprostinil (injection)

Definitions

Definitions of Treprostinil (injection)

Patient Resources / Community

Patient resources on Treprostinil (injection)

Discussion groups on Treprostinil (injection)

Patient Handouts on Treprostinil (injection)

Directions to Hospitals Treating Treprostinil (injection)

Risk calculators and risk factors for Treprostinil (injection)

Healthcare Provider Resources

Symptoms of Treprostinil (injection)

Causes & Risk Factors for Treprostinil (injection)

Diagnostic studies for Treprostinil (injection)

Treatment of Treprostinil (injection)

Continuing Medical Education (CME)

CME Programs on Treprostinil (injection)

International

Treprostinil (injection) en Espanol

Treprostinil (injection) en Francais

Business

Treprostinil (injection) in the Marketplace

Patents on Treprostinil (injection)

Experimental / Informatics

List of terms related to Treprostinil (injection)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Treprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension. Treprostinil is marketed as Remodulin®.

Clinical pharmacology

As an analogue of prostacyclin PGI2, treprostinil effects vasodilation, which in turn lowers the blood pressure. Treprostinil also inhibits platelet aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.

Dosage and administration

Treprostinil is administered via a small infusion pump that the patient must wear at all times. Treprostinil is preferentially given subcutaneously using an infusion set, but may be given intravenously via a central venous catheter if the patient is unable to tolerate the potential pain and discomfort of subcutaneous administration.

Treprostinil, under the trademark Remodulin®, is supplied in 20 mL vials, ranging in concentrations of 1 mg/mL, 2.5 mg/mL, 5 mg/mL, and 10 mg/mL. Treprostinil can be administered subcutaneously as supplied. It must be diluted for intravenous infusion with either sterile water or a 0.9% sodium chloride solution prior to administration.

The infusion rate is normally initiated at 1.25 ng/kg/min for new patients, but may be reduced to 0.625 ng/kg/min if the normal rate provokes unwanted side effects in the patient. The infusion rate of trepostinil should be increased no more than 1.25 ng/kg/min per week for the first month, then no more than 2.5 ng/kg/min per week for the remaining duration of infusion. The infusion rate should ideally be high enough to improve symptoms of pulmonary hypertension, while minimizing unpleasant side effects.

Oral and inhaled forms of treprostinil are currently undergoing clinical trials.

Important safety information

Precautions:

  • Because of treprostinil's inhibiting effect on platelet aggregation, there is an increased risk of bleeding, especially among patients who are also taking anticoagulants.
  • It is not known whether treprostinil is excreted in breast milk. Caution is advised when administering this medication to nursing women.

Common side effects:


Warnings:

  • Abrupt interruption of the treprostinil infusion can lead to worsening of pulmonary hypertension symptoms, and should be avoided.

Template:PAH rx Template:Prostaglandins


Template:WikiDoc Sources